Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
- PMID: 21592994
- PMCID: PMC3096784
- DOI: 10.1093/infdis/jir134
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
Abstract
Background: Substantial morbidity occurs during the first year of antiretroviral therapy (ART) in persons with advanced human immunodeficiency virus (HIV) disease despite HIV suppression. Biomarkers may identify high-risk groups.
Methods: Pre-ART and 1-month samples from an initial ART trial were evaluated for biomarkers associated with AIDS events or death within 1-12 months. Case patients (n = 63) and control patients (n = 126) were 1:2 matched on baseline CD4 cell count, hepatitis status, and randomization date. All had ≥ 1 log(10) HIV RNA level decrease at 1 month.
Results: Case patients had more frequent prior AIDS events, compared with control patients (P = .004), but similar HIV RNA levels at baseline. Pre-ART and 1-month C-reactive protein (CRP), D-dimer, and interleukin 6 (IL-6) levels and pre-ART hyaluronic acid (HA) levels were associated with new AIDS events or death (P ≤ .01). Patients who experienced immune reconstitution inflammatory syndrome (IRIS) events had higher pre-ART tumor necrosis factor α (TNF-α) and HIV RNA levels and significant 1-month increases in CRP, D-dimer, IL-6, interleukin 8, CXCL10, TNF-α, and interferon-γ levels, compared with patients who experienced non-IRIS events (P ≤ .03). Individuals with baseline CRP and HA levels above the cohort median (>2.1 mg/L and >50.0 ng/mL, respectively) had increased risk of AIDS or death (OR, 4.6 [95% CI, 2.0-10.3]; P < .001) and IRIS (OR, 8.7 [95% CI, 2.2-34.8] P = .002).
Conclusions: Biomarkers of Inflammation (CRP, IL-6), coagulation (D-dimer), and tissue fibrosis (HA) measured pre-ART and at 1 month are associated with higher risk of AIDS events, IRIS, or death, warranting additional study as risk stratification strategies.
Figures

Similar articles
-
d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS.Clin Immunol. 2010 Jul;136(1):42-50. doi: 10.1016/j.clim.2010.02.010. Epub 2010 Mar 15. Clin Immunol. 2010. PMID: 20227921 Free PMC article.
-
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.PLoS One. 2016 Apr 18;11(4):e0152588. doi: 10.1371/journal.pone.0152588. eCollection 2016. PLoS One. 2016. PMID: 27088215 Free PMC article.
-
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.PLoS Med. 2010 Dec 21;7(12):e1000384. doi: 10.1371/journal.pmed.1000384. PLoS Med. 2010. PMID: 21253011 Free PMC article.
-
Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis.Curr Opin HIV AIDS. 2010 Nov;5(6):504-10. doi: 10.1097/COH.0b013e32833ed774. Curr Opin HIV AIDS. 2010. PMID: 20966640 Free PMC article. Review.
-
HIV & immune reconstitution inflammatory syndrome (IRIS).Indian J Med Res. 2011 Dec;134(6):866-77. doi: 10.4103/0971-5916.92632. Indian J Med Res. 2011. PMID: 22310819 Free PMC article. Review.
Cited by
-
Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda.AIDS Care. 2020 Nov;32(11):1451-1456. doi: 10.1080/09540121.2020.1776822. Epub 2020 Jun 15. AIDS Care. 2020. PMID: 32539474 Free PMC article.
-
Classical complement and inflammasome activation converge in CD14highCD16- monocytes in HIV associated TB-immune reconstitution inflammatory syndrome.PLoS Pathog. 2021 Mar 31;17(3):e1009435. doi: 10.1371/journal.ppat.1009435. eCollection 2021 Mar. PLoS Pathog. 2021. PMID: 33788899 Free PMC article.
-
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection.J Infect Dis. 2016 Aug 1;214(3):408-16. doi: 10.1093/infdis/jiw173. Epub 2016 Apr 30. J Infect Dis. 2016. PMID: 27132283 Free PMC article.
-
Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study.Clin Infect Dis. 2016 Oct 1;63(7):984-990. doi: 10.1093/cid/ciw409. Epub 2016 Jun 25. Clin Infect Dis. 2016. PMID: 27343547 Free PMC article.
-
Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.J Infect Dis. 2013 Dec 1;208(11):1784-93. doi: 10.1093/infdis/jit368. Epub 2013 Aug 1. J Infect Dis. 2013. PMID: 23908475 Free PMC article.
References
-
- Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
-
- Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60. - PubMed
-
- Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9. - PubMed
-
- Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135:17–26. - PubMed
-
- Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965–72. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01AI042170/AI/NIAID NIH HHS/United States
- L30 AI066779/AI/NIAID NIH HHS/United States
- K23AI073192-02/AI/NIAID NIH HHS/United States
- K24 AI096925/AI/NIAID NIH HHS/United States
- U01AI046362/AI/NIAID NIH HHS/United States
- MC_U122886352/MRC_/Medical Research Council/United Kingdom
- K12RR023247-05/RR/NCRR NIH HHS/United States
- K23 AI073192/AI/NIAID NIH HHS/United States
- U01AI068641/AI/NIAID NIH HHS/United States
- K23 AI073192-03/AI/NIAID NIH HHS/United States
- L30 AI066779-05/AI/NIAID NIH HHS/United States
- KL2 RR033182/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous